MONOPAR THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
MONOPAR THERAPEUTICS INC. - More news...
MONOPAR THERAPEUTICS INC. - More news...
- Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
- Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
- Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
- Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
- Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
- Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
- Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
- Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
- Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
- Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
- Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
- Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
- Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
- Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
- Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
- Monopar and NorthStar Amend & Extend Collaboration
- Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
- Monopar Announces CFO Succession
- Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
- Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
